

Cedric Menard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3452300/publications.pdf>

Version: 2024-02-01

40
papers

4,590
citations

236925

25
h-index

330143

37
g-index

41
all docs

41
docs citations

41
times ranked

6826
citing authors

#	ARTICLE	IF	CITATIONS
1	Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. <i>Blood</i> , 2022, 140, 1822-1826.	1.4	8
2	Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma. <i>Blood Advances</i> , 2021, 5, 2063-2074.	5.2	11
3	Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells. <i>Stem Cells</i> , 2020, 38, 146-159.	3.2	50
4	Rituximab for auto-immune alveolar proteinosis, a real life cohort study. <i>Respiratory Research</i> , 2018, 19, 74.	3.6	32
5	NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment. <i>Oncolmunology</i> , 2018, 7, e1409322.	4.6	25
6	POFA trial study protocol: a multicentre, double-blind, randomised, controlled clinical trial comparing opioid-free versus opioid anaesthesia on postoperative opioid-related adverse events after major or intermediate non-cardiac surgery. <i>BMJ Open</i> , 2018, 8, e020873.	1.9	25
7	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. <i>Blood</i> , 2018, 132, 1486-1494.	1.4	25
8	Brief Report: Proteasomal Indoleamine 2,3-Dioxygenase Degradation Reduces the Immunosuppressive Potential of Clinical Grade-Mesenchymal Stromal Cells Undergoing Replicative Senescence. <i>Stem Cells</i> , 2017, 35, 1431-1436.	3.2	40
9	Mechanically Isolated Stromal Vascular Fraction Provides a Valid and Useful Collagenase-Free Alternative Technique: A Comparative Study. <i>Plastic and Reconstructive Surgery</i> , 2017, 139, 572e-573e.	1.4	0
10	Regulatory myeloid cells: an underexplored continent in B-cell lymphomas. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1103-1111.	4.2	19
11	Liposuction Preserves the Morphological Integrity of the Microvascular Network: Flow Cytometry and Confocal Microscopy Evidence in a Controlled Study. <i>Aesthetic Surgery Journal</i> , 2016, 36, 609-618.	1.6	49
12	Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. <i>Journal of Autoimmunity</i> , 2015, 62, 22-30.	6.5	40
13	Effects of a Ceramic Biomaterial on Immune Modulatory Properties and Differentiation Potential of Human Mesenchymal Stromal Cells of Different Origin. <i>Tissue Engineering - Part A</i> , 2015, 21, 767-781.	3.1	15
14	Medial Thighplasty After Massive Weight Loss: Are There Any Risk Factors for Postoperative Complications?. <i>Aesthetic Plastic Surgery</i> , 2014, 38, 63-68.	0.9	27
15	Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis?. <i>Blood</i> , 2014, 123, 3462-3465.	1.4	44
16	Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression. <i>Journal of Clinical Investigation</i> , 2014, 124, 5337-5351.	8.2	96
17	Comparative Study of Immune Regulatory Properties of Stem Cells Derived from Different Tissues. <i>Stem Cells and Development</i> , 2013, 22, 2990-3002.	2.1	89
18	Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. <i>Stem Cell Research and Therapy</i> , 2013, 4, 64.	5.5	61

#	ARTICLE	IF	CITATIONS
19	Clinical-Grade Mesenchymal Stromal Cells Produced Under Various Good Manufacturing Practice Processes Differ in Their Immunomodulatory Properties: Standardization of Immune Quality Controls. <i>Stem Cells and Development</i> , 2013, 22, 1789-1801.	2.1	186
20	Effects Of a Novel Ceramic Biomaterial On Immune Modulatory Properties and Differentiation Potential Of Mesenchymal Stromal Cells. <i>Blood</i> , 2013, 122, 4858-4858.	1.4	0
21	Quality Controls Of Immune Regulatory Properties Of Ex-Vivo, GMP-Grade Expanded Mesenchymal Stromal Cells For Clinical Use. <i>Blood</i> , 2013, 122, 5413-5413.	1.4	0
22	Immune Regulatory Properties Are a Common Feature Of Stem Cells. <i>Blood</i> , 2013, 122, 5419-5419.	1.4	0
23	Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. <i>Blood</i> , 2012, 119, 2556-2567.	1.4	133
24	Iterative Germinal Center Re-Entries of Memory B-Cells with t(14;18) Translocation and Early Steps of Follicular Lymphoma Progression. <i>Blood</i> , 2012, 120, 150-150.	1.4	3
25	Labeling of mesenchymal stromal cells with iron oxideâ€“poly(l-lactide) nanoparticles for magnetic resonance imaging: uptake, persistence, effects on cellular function and magnetic resonance imaging properties. <i>Cytotherapy</i> , 2011, 13, 962-975.	0.7	30
26	Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. <i>Nature Medicine</i> , 2011, 17, 700-707.	30.7	282
27	Follicular Lymphoma-Like B Cells In Healthy Individuals Are Released From Pretumoral Niches Established In Secondary Lymphoid Tissues. <i>Blood</i> , 2010, 116, 466-466.	1.4	4
28	Natural Killer Cell IFN- γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumorâ€“Bearing Patients. <i>Cancer Research</i> , 2009, 69, 3563-3569.	0.9	181
29	Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1579-1587.	4.2	137
30	Dendritic cells and innate defense against tumor cells. <i>Cytokine and Growth Factor Reviews</i> , 2008, 19, 79-92.	7.2	49
31	The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2. <i>Journal of Immunology</i> , 2008, 180, 6477-6483.	0.8	44
32	CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?. <i>Clinical Cancer Research</i> , 2008, 14, 5242-5249.	7.0	104
33	Therapy-Induced Tumor Immunosurveillance Involves IFN-Producing Killer Dendritic Cells: Figure 1.. <i>Cancer Research</i> , 2007, 67, 851-853.	0.9	33
34	Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 641-648.	4.2	1,104
35	The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. <i>Immunological Reviews</i> , 2006, 214, 229-238.	6.0	235
36	A novel dendritic cell subset involved in tumor immunosurveillance. <i>Nature Medicine</i> , 2006, 12, 214-219.	30.7	377

#	ARTICLE	IF	CITATIONS
37	Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines. Journal of Immunology, 2006, 176, 2722-2729.	0.8	192
38	IL-2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodes. European Journal of Immunology, 2005, 35, 2840-2850.	2.9	12
39	CD4 ⁺ CD25 ⁺ regulatory T cells inhibit natural killer cell functions in a transforming growth factor β 2-dependent manner. Journal of Experimental Medicine, 2005, 202, 1075-1085.	8.5	806
40	Stability of Cyclophosphamide and Mesna Admixtures in Polyethylene Infusion Bags. Annals of Pharmacotherapy, 2003, 37, 1789-1792.	1.9	12